JP5656643B2 - ナノ分散体 - Google Patents

ナノ分散体 Download PDF

Info

Publication number
JP5656643B2
JP5656643B2 JP2010540226A JP2010540226A JP5656643B2 JP 5656643 B2 JP5656643 B2 JP 5656643B2 JP 2010540226 A JP2010540226 A JP 2010540226A JP 2010540226 A JP2010540226 A JP 2010540226A JP 5656643 B2 JP5656643 B2 JP 5656643B2
Authority
JP
Japan
Prior art keywords
nanodispersion
paclitaxel
present
acid
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010540226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011507946A (ja
JP2011507946A5 (OSRAM
Inventor
アジャイ、ジャイシン、コペイド
スブハス、バララム、ボウミック
エヌ．アルルスダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharma Advanced Research Co Ltd
Original Assignee
Sun Pharma Advanced Research Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40853553&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5656643(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharma Advanced Research Co Ltd filed Critical Sun Pharma Advanced Research Co Ltd
Publication of JP2011507946A publication Critical patent/JP2011507946A/ja
Publication of JP2011507946A5 publication Critical patent/JP2011507946A5/ja
Application granted granted Critical
Publication of JP5656643B2 publication Critical patent/JP5656643B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
JP2010540226A 2007-12-24 2008-12-23 ナノ分散体 Active JP5656643B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2527MU2007 2007-12-24
IN2527/MUM/2007 2007-12-24
PCT/IN2008/000857 WO2009087678A2 (en) 2007-12-24 2008-12-23 Nanodispersion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014237028A Division JP5937180B2 (ja) 2007-12-24 2014-11-21 ナノ分散体

Publications (3)

Publication Number Publication Date
JP2011507946A JP2011507946A (ja) 2011-03-10
JP2011507946A5 JP2011507946A5 (OSRAM) 2013-11-28
JP5656643B2 true JP5656643B2 (ja) 2015-01-21

Family

ID=40853553

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010540226A Active JP5656643B2 (ja) 2007-12-24 2008-12-23 ナノ分散体
JP2014237028A Expired - Fee Related JP5937180B2 (ja) 2007-12-24 2014-11-21 ナノ分散体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014237028A Expired - Fee Related JP5937180B2 (ja) 2007-12-24 2014-11-21 ナノ分散体

Country Status (20)

Country Link
US (2) US8586062B2 (OSRAM)
EP (2) EP2231144B1 (OSRAM)
JP (2) JP5656643B2 (OSRAM)
KR (1) KR101505419B1 (OSRAM)
CN (1) CN101909614B (OSRAM)
AP (1) AP2895A (OSRAM)
AU (1) AU2008346121B2 (OSRAM)
BR (1) BRPI0821514B8 (OSRAM)
CA (1) CA2710525C (OSRAM)
CO (1) CO6290681A2 (OSRAM)
DK (1) DK2231144T3 (OSRAM)
EA (1) EA016434B1 (OSRAM)
ES (1) ES2509490T3 (OSRAM)
IL (1) IL206584A0 (OSRAM)
MX (1) MX2010007076A (OSRAM)
NZ (1) NZ586343A (OSRAM)
PL (1) PL2231144T3 (OSRAM)
UA (1) UA100543C2 (OSRAM)
WO (1) WO2009087678A2 (OSRAM)
ZA (1) ZA201004450B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8778364B2 (en) * 2009-06-19 2014-07-15 Sun Pharma Advanced Research Company Ltd. Nanodispersion of a drug and process for its preparation
CN102038635A (zh) * 2009-10-23 2011-05-04 天津天士力集团有限公司 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
KR20110056042A (ko) * 2009-11-20 2011-05-26 주식회사유한양행 종양세포 표적지향을 위한 나노 입자 및 이의 제조방법
JP5824511B2 (ja) 2010-05-03 2015-11-25 テイコク ファーマ ユーエスエー インコーポレーテッド 非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法
ES2385995B2 (es) * 2011-01-10 2013-05-21 Universidade De Santiago De Compostela Nanocápsulas con cubierta polimérica
CN102078300B (zh) * 2011-01-27 2012-01-11 海南美大制药有限公司 托拉塞米脂质体固体制剂
CN102366409B (zh) * 2011-09-14 2013-03-20 海南灵康制药有限公司 一种尼扎替丁脂质体固体制剂
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
BR112015022231B1 (pt) * 2013-03-14 2020-11-24 Griffith Laboratories International, Inc. Metodo para tratamento de fungos que causam sigatoka negra em plantaqoes da familia musaceae
US20170099833A1 (en) * 2014-05-30 2017-04-13 Oms Investments, Inc. Nano-sized water-based dispersion compositions and methods of making thereof
KR101692314B1 (ko) * 2015-03-27 2017-01-03 주식회사 주빅 지용성 약물의 생분해성 고분자 내 용해 시스템: 스마트 폴리머 시스템
US20160346219A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
JP2018516964A (ja) * 2015-06-09 2018-06-28 サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドＳｕｎ Ｐｈａｒｍａ Ａｄｖａｎｃｅｄ Ｒｅｓｅａｒｃｈ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ 局所進行性または転移性である肝内もしくは肝外胆管または胆嚢のカルシノーマに罹患する患者を治療する方法
CN107551390A (zh) * 2017-08-21 2018-01-09 常熟佳禾生物科技有限公司 一种用于治疗乳腺小叶增生的中药文胸贴片及其制备方法
JP7383626B2 (ja) * 2018-03-19 2023-11-20 エピクワイティー ファーマ アーべー カルシウム欠乏に起因する状態の治療に使用するための組成物
US11423574B2 (en) 2019-12-17 2022-08-23 Emma Ruccio Method and apparatus for detecting scoliosis
US11877717B2 (en) 2019-12-17 2024-01-23 Emma Ruccio Method and apparatus for detecting scoliosis
EP3928772B1 (en) * 2020-06-26 2024-06-19 Algiax Pharmaceuticals GmbH Nanoparticulate composition
JP7745863B2 (ja) * 2021-04-12 2025-09-30 国立大学法人広島大学 難水溶性物質の可溶化方法および難水溶性物質の可溶化組成物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6018A (en) * 1849-01-09 Improvement in bog-cutters
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
KR19990075621A (ko) * 1998-03-23 1999-10-15 임성주 경사 평판형 배양조
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
US6365191B1 (en) * 1999-02-17 2002-04-02 Dabur Research Foundation Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
WO2001021174A1 (en) * 1999-09-23 2001-03-29 Dabur Research Foundation Formulations of paclitaxel entrapped into nanoparticles of polymeric micelles
TWI230616B (en) * 2000-09-25 2005-04-11 Ind Tech Res Inst Liposome for incorporating large amounts of hydrophobic substances
CA2445763A1 (en) * 2001-05-01 2002-11-07 Angiotech Pharmaceuticals Inc. Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
DE10124952A1 (de) * 2001-05-21 2002-12-12 Bayer Ag Verfahren zur Herstellung von Nanodispersionen
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
US6780324B2 (en) 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
ITMI20022323A1 (it) * 2002-10-31 2004-05-01 Maria Rosa Gasco Composizioni farmaceutiche atte al trattamento di malattie oftalmiche.
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US7345093B2 (en) * 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US20050288521A1 (en) * 2004-06-29 2005-12-29 Phytogen Life Sciences Inc. Semi-synthetic conversion of paclitaxel to docetaxel
MX2007010394A (es) * 2005-02-24 2008-02-19 Elan Pharma Int Ltd Formulaciones nanoparticuladas de docetaxel y analogos del mismo.
EP2138164A1 (en) 2005-06-17 2009-12-30 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
CA2626016A1 (en) * 2005-10-21 2007-06-21 Panacea Biotec Limited Pharmaceutical composition comprising at least one anticancer drug and at least one polymer
KR100917809B1 (ko) * 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
US20100068251A1 (en) * 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof

Also Published As

Publication number Publication date
KR20100112564A (ko) 2010-10-19
CA2710525A1 (en) 2009-07-16
NZ586343A (en) 2012-03-30
AP2895A (en) 2014-05-31
AU2008346121B2 (en) 2013-10-10
CN101909614A (zh) 2010-12-08
US20100297244A1 (en) 2010-11-25
EP2853264A1 (en) 2015-04-01
US20140030352A1 (en) 2014-01-30
EP2231144A4 (en) 2011-01-12
JP2011507946A (ja) 2011-03-10
PL2231144T3 (pl) 2014-12-31
EP2231144B1 (en) 2014-07-02
KR101505419B1 (ko) 2015-03-30
CA2710525C (en) 2017-08-22
MX2010007076A (es) 2010-09-30
BRPI0821514B1 (pt) 2020-03-10
DK2231144T3 (da) 2014-10-13
BRPI0821514A2 (pt) 2016-09-27
WO2009087678A2 (en) 2009-07-16
AU2008346121A1 (en) 2009-07-16
JP5937180B2 (ja) 2016-06-22
EP2231144A2 (en) 2010-09-29
AP2010005314A0 (en) 2010-08-31
CO6290681A2 (es) 2011-06-20
CN101909614B (zh) 2015-04-15
ZA201004450B (en) 2011-03-30
JP2015110565A (ja) 2015-06-18
UA100543C2 (ru) 2013-01-10
ES2509490T3 (es) 2014-10-17
BRPI0821514B8 (pt) 2021-05-25
EA016434B1 (ru) 2012-04-30
IL206584A0 (en) 2010-12-30
EA201070793A1 (ru) 2010-12-30
US8586062B2 (en) 2013-11-19
WO2009087678A3 (en) 2009-09-11

Similar Documents

Publication Publication Date Title
JP5937180B2 (ja) ナノ分散体
Bahari et al. The impact of variables on particle size of solid lipid nanoparticles and nanostructured lipid carriers; a comparative literature review
Sumera et al. Docetaxel‐loaded solid lipid nanoparticles: a novel drug delivery system
Utreja et al. Novel drug delivery systems for sustained and targeted delivery of anti-cancer drugs: current status and future prospects
WO2012028101A1 (zh) 一种难溶性药物的液体组合物及其制备方法
KR20070091051A (ko) 신규 약물 제제
US20120087959A1 (en) Nanodispersion of a drug and process for its preparation
EP2262369A1 (en) Lipid-oil-water nanoemulsion delivery system for microtubule-interacting agents
US20190110993A1 (en) Solid Nanoparticle Formulation of Water Insoluble Pharmaceutical Substances with Reduced Ostwald Ripening
CN103976950B (zh) 一种阿霉素纳米载药系统、其制备方法及其应用
WO2015095784A1 (en) Solid nanoparticle formulation of microtubule inhibitors with reduced ostwald ripening for oral administration
CN105853403A (zh) 一种紫杉醇棕榈酸酯脂质体及其制备方法
Zulfakar et al. Medium-chain triacylglycerols (MCTs) and their fractions in drug delivery systems: a systematic review
Yuk et al. Multi-core vesicle nanoparticles based on vesicle fusion for delivery of chemotherapic drugs
Lundberg Preparation and characterization of polymeric pH-sensitive STEALTH® nanoparticles for tumor delivery of a lipophilic prodrug of paclitaxel
Thotakura et al. Promises of lipid-based drug delivery systems in the management of breast cancer
Bhattacharya et al. Development of D-α-Tocopherol polyethylene glycol 1000 succinate fabricated nanostructural lipid carrier of sorafenib tosylate for metastatic colorectal targeting application: Stability, physical characterization, cytotoxicity, and apoptotic studies against SW48 cells PTEN
KR101180181B1 (ko) 나노 입자 및 그의 제조 방법
CN101632637B (zh) 一种多烯紫杉醇脂质制剂及其制备方法
Lee et al. Computed Tomography-Guided Screening of Surfactant Effect on Blood Circulation Time of Emulsions: Application to the Design of an Emulsion Formulation for Paclitaxel: Lee et al.
Feng Oil-filled Lipid Nanoparticles Containing Docetaxel Conjugates for Controlled Drug Release
BR102017015966B1 (pt) Nanocarreadores emulsionados catiônicos multifuncionais e usos dos mesmos

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130911

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130919

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20131011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140430

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141024

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141125

R150 Certificate of patent or registration of utility model

Ref document number: 5656643

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250